Dr Reddy's Laboratories on Wednesday said it has reduced the price of its cardiovascular drug Cidmus. The drug comprises combination of sacubitril and valsartan and is indicated for heart failure patients.
The company's Cidmus tablets are available in three strengths - 50mg, 100mg and 200mg, to be taken twice a day.
"Following the price reduction, Cidmus will be priced at Rs 29 for 50 mg (down from Rs 78.32); Rs 49 for 100 mg (down from Rs 83.86); Rs 79 for 200 mg (down from Rs 96.71) per tablet," the Hyderabad-based drug maker said in a statement.
This price reduction will further widen access to this trusted and established brand, it added.
Dr Reddy's acquired the Cidmus brand from Novartis AG in 2022 for the India market.
The company's Cidmus tablets are available in three strengths - 50mg, 100mg and 200mg, to be taken twice a day.
"Following the price reduction, Cidmus will be priced at Rs 29 for 50 mg (down from Rs 78.32); Rs 49 for 100 mg (down from Rs 83.86); Rs 79 for 200 mg (down from Rs 96.71) per tablet," the Hyderabad-based drug maker said in a statement.
This price reduction will further widen access to this trusted and established brand, it added.
Dr Reddy's acquired the Cidmus brand from Novartis AG in 2022 for the India market.
Read More News on
(Catch all the Business News, Breaking News Events and Latest News Updates on The Economic Times.)
...moreDownload The Economic Times News App to get Daily Market Updates & Live Business News.
